Moderna lifts 2026 revenue outlook for Covid vaccine sales

Key Points

Moderna updates its 2026 revenue/sales guidance upward.
The raised 2026 revenue growth outlook is described as a range up to about 25%.
NDTV reports Moderna shares rise 7.1% in premarket trading following the announcement.
Quartz reports an increased year-end cash outlook of about $8.1 billion to $8.3 billion.
CNBC includes CEO commentary that newer vaccines are gaining traction.

Where coverage differs

All outlets agree Moderna raises its 2026 revenue outlook and that the update supports a positive stock reaction (explicitly quantified by NDTV). Quartz is the only one provided that includes the cash outlook range ($8.1 billion to $8.3 billion) and frames the change as following a bigger-than-expected profit. MarketWatch and NDTV focus more on the stock/investor response, while CNBC adds an explanatory angle from the CEO about newer vaccines gaining traction. The reported revenue guidance is consistent across sources as a higher forecast, described as up to 25% and, in Quartz and CNBC, also as a 15%–25% range.

See what each outlet emphasised ↓

Moderna lifts 2026 revenue outlook for Covid vaccine sales

Photo: NDTV

Moderna raises its full-year 2026 sales guidance, and the stock reacts positively as investors respond to the improved outlook. NDTV reports shares rise 7.1% in premarket trading on Friday following the company’s update.

Quartz and MarketWatch both say Moderna increases its expected 2026 revenue growth, describing it as as much as 25% and noting it is higher than the prior forecast. Quartz adds more detail, stating the 2026 revenue growth range is 15% to 25% and that the company’s year-end cash outlook rises to between $8.1 billion and $8.3 billion. CNBC also frames the update around CEO commentary, saying newer vaccines are gaining traction alongside the stronger 2026 revenue outlook.

Across outlets, the central context is the same: Moderna improves its financial guidance for 2026, linked to Covid vaccine-related revenue expectations. The differences are mainly in what each outlet highlights—stock movement (NDTV), profit/outlook framing and cash figures (Quartz), technology-market focus (MarketWatch), and CEO rationale around newer vaccines (CNBC).

This summary is generated automatically from the reporting of the outlets listed on this page. Follow their links for the full coverage.